POPO
New member
- Messages
- 7
- Reaction score
- 1
- Points
- 3
Clinical Titration Protocol (Clinical Trial Reference, Not Medication Guidance)
Slow escalation is essential; gastrointestinal side effects are higher than with Tirzepatide.
Starting dose: 2 mg/week, maintenance for 4 weeks (tolerance build-up)
Assess tolerance every 4 weeks and escalate: 2 mg → 4 mg → 8 mg → 12 mg
Maximum study dose in clinical trials: 12 mg/week
Conservative regimen for sensitive populations: Start with 1 mg, gradually increasing the intervals. If significant nausea or vomiting occurs, maintain or reduce to the previous dose; do not attempt to tolerate side effects.
Dissolution, Reconstitution, and Storage (Research Practice)
Solubilizer: Bacteriostatic Water (BAC) is preferred; sterile water for injection is secondary; acetic acid reconstitution is prohibited.
Dissolution: Gently swirl to mix; vigorous shaking is strictly prohibited to prevent peptide chain breakage; A qualified solution should be colorless and completely clear. Turbidity, flocculent matter, or discoloration indicates degradation failure; discard immediately.
Unreconstituted lyophilized powder: Store at -20°C, protected from light, sealed, for long-term storage; store at 2-8°C for short-term storage only.
After reconstitution: Refrigerate at 2-8℃ and protect from light; use within 28 days under antibacterial conditions; use within 7 days under ordinary sterile conditions; never freeze the reconstituted solution.
Adverse Reactions (Generally similar to the GLP-1 family, but gastrointestinal reactions are stronger at the same dose):
Common: Nausea, vomiting, diarrhea, constipation, abdominal distension, decreased appetite, fatigue, headache, redness, swelling and itching at the injection site. Most are most pronounced 1-3 days after dose escalation, and gradually tolerated after 4-8 weeks.
Slow escalation is essential; gastrointestinal side effects are higher than with Tirzepatide.
Starting dose: 2 mg/week, maintenance for 4 weeks (tolerance build-up)
Assess tolerance every 4 weeks and escalate: 2 mg → 4 mg → 8 mg → 12 mg
Maximum study dose in clinical trials: 12 mg/week
Conservative regimen for sensitive populations: Start with 1 mg, gradually increasing the intervals. If significant nausea or vomiting occurs, maintain or reduce to the previous dose; do not attempt to tolerate side effects.
Dissolution, Reconstitution, and Storage (Research Practice)
Solubilizer: Bacteriostatic Water (BAC) is preferred; sterile water for injection is secondary; acetic acid reconstitution is prohibited.
Dissolution: Gently swirl to mix; vigorous shaking is strictly prohibited to prevent peptide chain breakage; A qualified solution should be colorless and completely clear. Turbidity, flocculent matter, or discoloration indicates degradation failure; discard immediately.
Unreconstituted lyophilized powder: Store at -20°C, protected from light, sealed, for long-term storage; store at 2-8°C for short-term storage only.
After reconstitution: Refrigerate at 2-8℃ and protect from light; use within 28 days under antibacterial conditions; use within 7 days under ordinary sterile conditions; never freeze the reconstituted solution.
Adverse Reactions (Generally similar to the GLP-1 family, but gastrointestinal reactions are stronger at the same dose):
Common: Nausea, vomiting, diarrhea, constipation, abdominal distension, decreased appetite, fatigue, headache, redness, swelling and itching at the injection site. Most are most pronounced 1-3 days after dose escalation, and gradually tolerated after 4-8 weeks.